Wuguo Li

Wuguo Li

Auto-generated profile, based on publicly available information

Wuguo Li

(a)The Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, PR China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WLWeihai Liu
Weihai Liu
ZZZhiqiang Zhao
Zhiqiang Zhao
YWYongqian Wang
Yongqian Wang
WLWuguo Li
Wuguo Li
QSQiao Su
Qiao Su
JYJunqiang Yin
Junqiang Yin
Osteosarcoma is the most common primary bone tumor in children and adolescents. Many patients with osteosarcoma always develop drug resistance to current chemotherapy regimens, which induces a poor prognosis. And cancer stem cells (CSCs) have been reported to possess the properties to self-renew and maintain the phenotype of tumor, which may lead to clinical treatment failure. Thus, it is an urgent task to develop several potentially useful therapeutic agents, which could target CSCs in osteosarcoma. This study aims to clarify the in vitro and in vivo anti-osteosarcoma effects of dioscin, the primary component derived from Discorea nipponica Makino, and its molecular mechanism of action. In this study, all the ten human osteosarcoma cell lines were sensitive to dioscin treatment in a dose- and time-dependent manner. Dioscin inhibits proliferation and induces cell cycle arrest as well as apoptotic cell death in osteosarcoma cells. More importantly, oral administration of dioscin (60 mg/kg) showed significant therapeutic effect on osteosarcoma growth without obvious side effects in vivo. In addition, dioscin possesses the ability to suppress stem-cell-like phenotype of osteosarcoma cells. Mechanistically, dioscin inhibits osteosarcoma stem-cell-like properties and tumor growth through repression of Akt/GSK3/β-catenin pathway. Moreover, β-catenin expression in osteosarcoma patients was associated with clinical prognosis. Conclusively, the present study provides comprehensive evidence for the inhibition of dioscin on osteosarcoma stem-cell-like properties and tumor growth through repression of Akt/GSK3/β-catenin pathway, which suggests dioscin as a promising therapeutic regimen. And β-catenin may be a potential therapeutic target as well as a significant prognostic marker for osteosarcoma patients in clinic.

1 August 2018 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
QDQianqian Deng
Qianqian Deng
GJGuanmin Jiang
Guanmin Jiang
YWYingmin Wu
Yingmin Wu
JLJiexin Li
Jiexin Li
WLWeiting Liang
Weiting Liang
HWHongsheng Wang
Hongsheng Wang

1 June 2019 in Journal of Autoimmunity
Verified
Journal Article
Open access
QSQiao Su
Qiao Su
JJJun Jing
Jun Jing
WLWuguo Li
Wuguo Li
JMJianda Ma
Jianda Ma
XZXueling Zhang
Xueling Zhang
LSLan Shao
Lan Shao
In rheumatoid arthritis (RA), imbalanced T cells subsets play a critical role in sustaining chronic inflammatory responses in the synovium. Naïve T cells in RA patients undergo maldifferentiation, including an increase in the effector Th1/Th17 lineage and a reduction in regulatory T (Treg) cells. Upon stimulation, naïve CD4+CD45RO- T cells from RA patients exhibited insufficient expression of Foxp3, which induced a deficiency in Tregs production and an imbalance of Treg/Th17 differentiation. Further mechanistic study indicated that RA T cells failed to produce sufficient levels of the histone acetyltransferase Tip60, leading to reduced acetylation of Foxp3; this, in turn, decreased Foxp3 expression, impaired Treg commitment, and promoted Th17 production. Moreover, in human synovium chimeric mice, suppression of Tip60 activity in healthy T cells promoted tissue infiltration and arthritogenesis, while reconstitution of Tip60 in RA T cells suppressed synovitis and effector T cell infiltration. Our findings link T cell maldifferentiation and tissue infiltration with Tip60-mediated Foxp3 acetylation and identify Tip60 as a potential therapeutic target for suppression of tissue inflammation and autoimmunogenesis in RA.

1 July 2014 in Phytomedicine
Verified
Journal Article
Closed access
JLJiawei Liu
Jiawei Liu
QZQing Zhang
Qing Zhang
YYYushan Ye
Yushan Ye
WLWuguo Li
Wuguo Li
JQJunxin Qiu
Junxin Qiu
QYQiang Yu
Qiang Yu

3 March 2014 in Cancer Science
Verified
Journal Article
Open access
PDF file
SKShan Kuang
Shan Kuang
CQChunting Qi
Chunting Qi
JLJiawei Liu
Jiawei Liu
XSXiaoxiao Sun
Xiaoxiao Sun
QZQing Zhang
Qing Zhang
QYQiang Yu
Qiang Yu
Constitutive activation of the signal transducer and activator of transcription 3 (STAT3) or the nuclear factor-κB (NF-κB) pathway occurs frequently in cancer cells and contributes to oncogenesis. The activation of Janus kinase 2 (JAK2) and IκB kinase (IKK) are key events in STAT3 and NF-κB signaling, respectively. We have identified 2-methoxystypandrone (2-MS) from a traditional Chinese medicinal herb Polygonum cuspidatum as a novel dual inhibitor of JAK2 and IKK. 2-MS inhibits both interleukin-6-induced and constitutively-activated STAT3, as well as tumor necrosis factor-α-induced NF-κB activation. 2-MS specifically inhibits JAK and IKKβ kinase activities but has little effect on activities of other kinases tested. The inhibitory effects of 2-MS on STAT3 and NF-κB signaling can be eliminated by DTT or glutathione and can last for 4 h after a pulse treatment. Furthermore, 2-MS inhibits growth and induces death of tumor cells, particularly those with constitutively-activated STAT3 or NF-κB signaling. We propose that the natural compound 2-MS, as a potent dual inhibitor of STAT3 and NF-κB pathways, is a promising anticancer drug candidate.

4 June 2018 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SKShan Kuang
Shan Kuang
ZSZhenhua Sima
Zhenhua Sima
JLJiawei Liu
Jiawei Liu
WLWuguo Li
Wuguo Li
QSQiaoling Song
Qiaoling Song
QYQiang Yu
Qiang Yu
Background: 2-Methoxystypandrone (2-MS), isolated from the roots of Polygonum cuspidatum, is a potent dual inhibitor of the STAT3 and NF-κB pathways. Objective: To investigate the molecular targets and mechanisms of 2-MS. Method: A biotin-conjugated 2-MS analog, named 2-MS-Biotin, was designed and synthesized. The effects of 2-MS-Biotin on the STAT3 and NF-κB pathways were examined by Western blotting. The cytotoxicity of 2- MS-Biotin was evaluated using real-time cell analysis system. Proteins directly bound to 2-MS-Biotin were pulled down through streptavidin agarose beads and were detected using Western blotting. Results: 2-MS-Biotin retained the inhibition activities of the parent compound 2-MS on the STAT3 and NF-κB pathways as well as on cancer cell growth. Also, JAK2 and IKK proteins can be effectively pulled down by 2- MS-Biotin. Conclusion: Using 2-MS-Biotin as a tool, both JAK2 and IKK were identified as the targets of 2-MS.